Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Ovarian Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × vofatamab × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡